Comparative Pharmacology
Head-to-head clinical analysis: DEPO PROVERA versus DEPO SUBQ PROVERA 104.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPO PROVERA versus DEPO SUBQ PROVERA 104.
DEPO-PROVERA vs DEPO-SUBQ PROVERA 104
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progestin that suppresses gonadotropin secretion, inhibiting ovulation and causing endometrial thinning.
Medroxyprogesterone acetate is a progestin that inhibits gonadotropin secretion, thereby inhibiting ovulation and causing endometrial thinning.
150 mg intramuscularly every 3 months (13 weeks) for contraception; for endometriosis, 50 mg subcutaneously once weekly or 150 mg intramuscularly every 90 days.
104 mg subcutaneously every 3 months (13 weeks). Administer into the anterior thigh or abdomen by a healthcare professional.
None Documented
None Documented
Terminal elimination half-life is approximately 12-17 hours after single dose, but after multiple doses or depot administration, the half-life extends to about 40-60 hours due to slow release from injection site.
Terminal elimination half-life is approximately 40 hours (range 20-80 hours) with chronic administration due to slow absorption from the depot; clinically, this allows for once-weekly dosing.
Primarily metabolized in the liver via hydroxylation and conjugation; metabolites are excreted in urine (60-70%) and feces (20-30%). Less than 1% excreted unchanged in urine.
Primarily metabolized in the liver; metabolites are excreted in urine (70-80%) and feces (20-30%). Less than 1% unchanged in urine.
Category C
Category C
Progestin-Only Contraceptive
Progestin-Only Contraceptive